- Home
- INV vs LYEL Comparison
INV vs LYEL Comparison
Compare INV & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- LYEL
- Stock Information
- Founded
- INV 2015
- LYEL 2018
- Country
- INV United States
- LYEL United States
- Employees
- INV N/A
- LYEL N/A
- Industry
- INV
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- INV
- LYEL Health Care
- Exchange
- INV NYSE
- LYEL Nasdaq
- Market Cap
- INV 173.3M
- LYEL 207.7M
- IPO Year
- INV N/A
- LYEL 2021
- Fundamental
- Price
- INV $4.69
- LYEL $12.44
- Analyst Decision
- INV Strong Buy
- LYEL Sell
- Analyst Count
- INV 2
- LYEL 2
- Target Price
- INV $14.00
- LYEL $15.00
- AVG Volume (30 Days)
- INV 71.1K
- LYEL 74.0K
- Earning Date
- INV 08-15-2025
- LYEL 08-11-2025
- Dividend Yield
- INV N/A
- LYEL N/A
- EPS Growth
- INV N/A
- LYEL N/A
- EPS
- INV N/A
- LYEL N/A
- Revenue
- INV $1,220,000.00
- LYEL $65,000.00
- Revenue This Year
- INV $1,045.66
- LYEL N/A
- Revenue Next Year
- INV $240.46
- LYEL N/A
- P/E Ratio
- INV N/A
- LYEL N/A
- Revenue Growth
- INV 18.27
- LYEL N/A
- 52 Week Low
- INV $3.00
- LYEL $7.65
- 52 Week High
- INV $18.75
- LYEL $34.40
- Technical
- Relative Strength Index (RSI)
- INV N/A
- LYEL 62.02
- Support Level
- INV N/A
- LYEL $9.11
- Resistance Level
- INV N/A
- LYEL $14.18
- Average True Range (ATR)
- INV 0.00
- LYEL 0.87
- MACD
- INV 0.00
- LYEL 0.37
- Stochastic Oscillator
- INV 0.00
- LYEL 66.21
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.